Issues
-
Cover Image
Cover Image
Nuclear active RSK2 (magenta, left) correlates with ERα (blue, right) in sixty percent of ER+ patients as visualized in this serial section from an ER+ tumor. In each section the cells were also stained for cytokeratin 8 (lime, left; magenta, right) and cytokeratin 14 (cyan, left; yellow, right). In the left image, cells that are positive for both K8 and K14 are teal and on the right, these dual-positive cells are orange. Sequestration of RSK2 by ERα in the nucleus drives a pro-neoplastic transcriptional program critical to the ER+ lineage in the mammary gland, neoplasia, and differing patient responses to antiestrogen therapies. For details, see article by Ludwik and colleagues on page 2014. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Editorial
Review
Point–Counterpoint Reviews
Genome and Epigenome
Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas
Metabolism and Chemical Biology
Molecular Cell Biology
Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma
Tumor Biology and Immunology
Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells
CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes
Translational Science
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer
Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
Convergence and Technologies
Resource Report
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.